SUBJECT>Re:kEtAnsErIn
POSTER>Joe
EMAIL>a_town@yahoo.com
DATE>Wednesday, 26 January 2000, at 11:03 p.m.
Actually if you search medline/pubmed you'll find that a majority of these antagonists/agonists have been tested on humans for various purposes, never for DP of course.
My current favorite, MDL 11,939, an orally active 5HT2 antagonist, was used in a study by Sramek et al to treat generalized anxiety disorder. The study found it not to be very effective as an anxiolytic. I think if any 5HT2 antagonist has a chance of being a "DP/DR-olytic", it is MDL 11,939.
However, in looking at 5HT2 receptors, I think we are fighting the battle "downstream". This is certainly the case in depression, and I think in Dp/DR as well. In depression, the stress system is overactive and cortisol levels are high. I've read cortisol levels are actually low in DPers. 5HT problems are an effect and not the cause. I'm starting to lean towards Alex's endogenous opioids theory, however, I think that the cannabinoid system also plays a part in DP/DR. All this happens "upstream" of the 5HT system. SR141716A has also been tested in humans, but only in those intoxicated with THC. Basically, nothing has been tested on DP/DR subjects except ssri's and benzos.
As far as ethics go, short of causing permanent brain damage, I don't think I can put my brain in a worse chemical situation than it is already in. If Celexa/Klono doesn't work, I'm going for MDL 11,939.
My viewpoints will probably change by tomorrow,
Joe